The limit to which serum β2-MG level could be lowered by an intermittent hemopurification approach

スポンサーリンク

概要

• 論文の詳細を見る

• We developed a too-pool kinetic model for β2-MG consisting of interstitial and plasma space and simulated the serum β2-MG concentration trends in patients with end-stage renal failure on hemodialysis for a long period of time. In this model, we supposed that 1) the generation rate would not change even if the β2-MG concentration fluctuated and 2) β2-MG degradation rate within the body between treatments was culculated as the product of the β2-MG concentration and time independent intrinsic clearance and further, 3) during an intermittent treatment β2-MG degradation rate was culculated as the product of the β2-MG concentration and the artificial kidney clearance plus 2). The results showed that a dramatic fall of serum β2-MG level could be expected right after treatment, however, a gradual rise of serum concentrations, which we call a rebound phenomenon, is observed between treatments. Asuming that a dialyzer clearance for β2-MG is 50ml/min and 4 hour dialysis is performed 3 times a week, estimated pre-dialysis serum levels of β2-MG after 2 weeks in patients with initial serum levels of 60, 40, and 20ml/l are 39.2, 30.8 and 18.4 mg/l, respectively, due mainly to the above mentioned rebound phenomenon. This means that a continuous fall of the serum concentration could not be obtained by a present method of intermittent hemopurification especially in patients with relatively lower serum β2-MG level among HD patients.

• 社団法人 日本透析医学会の論文

社団法人 日本透析医学会 | 論文

• 4．血液浄化療法の生体適合性と腎性貧血
• PD-HD併用療法においての腎機能保護の可能性 : 第51回日本透析医学会ワークショップより
• 腹部大動脈人工血管の仮性動脈瘤破裂，および右大腿回旋動脈の仮性動脈瘤破裂をきたした血液透析患者の1例
• 5．透析患者のインスリン抵抗性と腎性貧血
• 摘出腫瘤の病理組織標本所見より頸椎腫瘍状石灰沈着症 (cervical tumoral calcinosis) と診断し得た維持透析患者の1例

もっと見る

スポンサーリンク